February 20 | 2019

Correction – Lack of reference to MAR – 2cureX meddelar positiva resultat från pågående klinisk studie med kraftigt förbehandlade kolorektalcancerpatienter

Read more
February 20 | 2019

Correction – Lack of reference to MAR – 2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients

Read more
January 16 | 2019

2cureX strengthens the organisation via the recruitment of a CFO

Read more
January 16 | 2019

2cureX stärker organisationen genom rekrytering av CFO

Read more
December 10 | 2018

2cureX is accelerating the launch of IndiTreat®

Read more
December 10 | 2018

2cureX accelererar lanseringen av IndiTreat®

Read more
November 23 | 2018

2cureX AB publishes interim report for January – September 2018

Read more
November 23 | 2018

2cureX AB offentliggör delårsrapport för januari – september 2018

Read more
November 16 | 2018

Vejle universitetssjukhus och 2cureX har erhållit godkännande att inleda en klinisk studie i bukspottkörtelcancer

Read more
November 16 | 2018

The University Hospital, Vejle Hospital and 2cureX have received approval to start a clinical trial in pancreatic cancer

Read more
October 9 | 2018

2cureX announces CE-IVD marking of its IndiTreat test

Read more
October 9 | 2018

2cureX meddelar godkänd CE-IVD-märkning av sitt IndiTreat-test

Read more
August 24 | 2018

2cureX AB publishes interim report for the first half-year of 2018

Read more
August 24 | 2018

2cureX AB offentliggör halvårsrapport för det första halvåret 2018

Read more
August 22 | 2018

2cureX stärker sin patentportfölj med nytt godkänt europeiskt patent

Read more
August 22 | 2018

2cureX strengthen its patent portfolio with the granting of a new European patent

Read more
June 21 | 2018

2cureX presenterar positiva kliniska data från den kliniska studien med IndiTreat vid ESMO i Barcelona

Read more
June 21 | 2018

2cureX presents positive clinical data from its IndiTreat® CRC trial at ESMO in Barcelona

Read more